Format

Send to

Choose Destination
Cancer Invest. 2011 May;29(4):318-24. doi: 10.3109/07357907.2011.554477. Epub 2011 Feb 23.

Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling.

Author information

1
Department of Oral Diagnostic Service, College of Dentistry, Howard University, Washington, District of Columbia, USA.

Abstract

Prostate-specific antigen (PSA) test is limited in prostate cancer diagnosis due to its inaccuracy. A new approach which integrates the PSA test with miRNA profiling was investigated to improve prostate cancer diagnosis. Six prostate cancer-related miRNAs (miR-16, -21, -34c, -101, -125b, -141) were tested in five cultured prostate cell lines and 20 human prostate specimens. We found that the miRNA expression profiles were significantly different between nontumorigenic and tumorigenic cell lines and specimens. Positive predictive value analysis of prostate cancer was increased from 40% to 87.5% by integrating patient PSA blood levels with miR-21 and miR-141 profiles.

PMID:
21345070
PMCID:
PMC3305797
DOI:
10.3109/07357907.2011.554477
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center